PHILADELPHIA--(BUSINESS WIRE)--Dec. 13, 2005--Hemispherx Biopharma, Inc. (AMEX: HEB) announces that research published by an academic consortium led by The National Defense University (U.S.A.) in the Journal of Allergy and Clinical Immunology (JACI) (December issue) titled "Innate Immunity for Biodefense: A Strategy whose Time has Come" have found that Hemispherx products Alferon N(R) and Ampligen(R), are among a small pool of agents that stimulate innate immunity for the defense against a bio-terror attack. The study concluded that an adequate defense would require a broad-spectrum approach to combat deadly pathogens, such as the H5N1 virus. Alferon N(R) and Ampligen(R) have shown the greatest ability to stimulate the innate immune system (also called "the first line of defense") therefore providing the best opportunity to fulfill this requirement.
